摘要目的:探讨核基质蛋白22(NMP22)及E-钙黏蛋白(E-Cad)在膀胱癌早期诊断中的临床价值。方法:收集本院自2018年1月至2021年1月收治的61例确诊为原发性膀胱癌患者的尿液样本，设为膀胱癌组，并选取同期60例健康者的尿液样本作为对照组，采用酶免疫分析法测定两组NMP22表达水平及定量夹心酶免疫测定技术测定E-Cad表达水平。结果:与对照组相比，膀胱癌组的NMP22、E-Cad均升高，差异均有统计学意义(均 P<0.001)。在膀胱癌组中，淋巴结转移阳性患者的E-Cad水平显著高于淋巴结转移阴性患者，差异有统计学意义( P＝0.007)。受试者工作特征(ROC)曲线分析得出，NMP22诊断膀胱癌的灵敏度及特异度分别为84.4%和59.3%，E-Cad诊断膀胱癌的灵敏度及特异度分别为76.9%和50.0%。 结论:NMP22、E-Cad均可以作为检测膀胱癌的良好指标，联合NMP22及E-Cad检测可以弥补各指标检测的弊端，显著提高膀胱癌的早期诊断率。

abstractsObjective:To investigate the application of nuclear matrix protein 22 (NMP22) and E-cadherin (E-Cad) in the early diagnosis of bladder cancer.Methods:Urine samples of 61 patients diagnosed with primary bladder cancer in our hospital from January 2018 to January 2021 were collected and set as bladder cancer group, and urine samples of 60 healthy people in the same period were selected as control group.Enzyme immunoassay and quantitative sandwich enzyme immunoassay were used to detect NMP22 and E-Cad.Results:Compared with the control group, NMP22 and E-cad in the bladder cancer group were significantly higher (all P<0.001). In bladder cancer group, the level of E-Cad in patients with positive lymph node metastasis was significantly higher than that in patients with negative lymph node metastasis, and the difference was statistically significant ( P=0.007). ROC curve analysis showed that the sensitivity and specificity of NMP22 were 84.4% and 59.3% respectively. The sensitivity and specificity of E-Cad in the diagnosis of bladder cancer were 76.9% and 50.0% respectively. Conclusions:NMP22, E-Cad can be used as a good index for detection of bladder cancer, combined with NMP22 and E-Cad can make up for the shortcomings of each index, and improve the early diagnosis of bladder cancer.